{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:02:10Z","timestamp":1792087330584,"version":"4.4.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,7,29]],"date-time":"2018-07-29T00:00:00Z","timestamp":1532822400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s00277-018-3446-y","type":"journal-article","created":{"date-parts":[[2018,7,28]],"date-time":"2018-07-28T18:34:27Z","timestamp":1532802867000},"page":"2425-2436","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect\u00ae MM Registry"],"prefix":"10.1007","volume":"97","author":[{"given":"Rafat","family":"Abonour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.M.","family":"Durie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohit","family":"Narang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard R.","family":"Terebelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina J.","family":"Gasparetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Toomey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Hardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amani","family":"Kitali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig J.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene S.","family":"Swern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Rifkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,29]]},"reference":[{"key":"3446_CR1","unstructured":"NCI (2017) SEER Cancer Stat Facts: Myeloma National Cancer Institute https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html . Accessed 4\/3\/2017 2017"},{"issue":"1","key":"3446_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21387","journal-title":"CA Cancer J Clin"},{"issue":"14","key":"3446_CR3","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, Arnulf B, Macro M, Belhadj K, Garderet L, Roussel M, Payen C, Mathiot C, Fermand JP, Meuleman N, Rollet S, Maglio ME, Zeytoonjian AA, Weller EA, Munshi N, Anderson KC, Richardson PG, Facon T, Avet-Loiseau H, Harousseau JL, Moreau P, Study IFM (2017) Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med 376(14):1311\u20131320. https:\/\/doi.org\/10.1056\/NEJMoa1611750","journal-title":"N Engl J Med"},{"key":"3446_CR4","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1038\/leu.2016.381","volume":"31","author":"F Gay","year":"2017","unstructured":"Gay F, Oliva S, Petrucci MT, Montefusco V, Conticello C, Musto P, Catalano L, Evangelista A, Spada S, Campbell P, Ria R, Salvini M, Offidani M, Carella AM, Omede P, Liberati AM, Troia R, Cafro AM, Malfitano A, Falcone AP, Caravita T, Patriarca F, Nagler A, Spencer A, Hajek R, Palumbo A, Boccadoro M (2017) Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis. Leukemia 31:1727\u20131734. https:\/\/doi.org\/10.1038\/leu.2016.381","journal-title":"Leukemia"},{"issue":"10","key":"3446_CR5","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1056\/NEJMoa1402888","volume":"371","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT, Pezzatti S, Caravita T, Cerrato C, Ribakovsky E, Genuardi M, Cafro A, Marcatti M, Catalano L, Offidani M, Carella AM, Zamagni E, Patriarca F, Musto P, Evangelista A, Ciccone G, Omede P, Crippa C, Corradini P, Nagler A, Boccadoro M, Cavo M (2014) Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 371(10):895\u2013905. https:\/\/doi.org\/10.1056\/NEJMoa1402888","journal-title":"N Engl J Med"},{"issue":"26","key":"3446_CR6","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa032290","volume":"349","author":"M Attal","year":"2003","unstructured":"Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, Monconduit M, Hulin C, Caillot D, Bouabdallah R, Voillat L, Sotto JJ, Grosbois B, Bataille R, InterGroupe Francophone d M (2003) Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349(26):2495\u20132502. https:\/\/doi.org\/10.1056\/NEJMoa032290","journal-title":"N Engl J Med"},{"issue":"2","key":"3446_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"M Attal","year":"1996","unstructured":"Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335(2):91\u201397. https:\/\/doi.org\/10.1056\/NEJM199607113350204","journal-title":"N Engl J Med"},{"issue":"19","key":"3446_CR8","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","volume":"366","author":"M Attal","year":"2012","unstructured":"Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, Stoppa AM, Hulin C, Benboubker L, Garderet L, Decaux O, Leyvraz S, Vekemans MC, Voillat L, Michallet M, Pegourie B, Dumontet C, Roussel M, Leleu X, Mathiot C, Payen C, Avet-Loiseau H, Harousseau JL, Investigators IFM (2012) Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 366(19):1782\u20131791. https:\/\/doi.org\/10.1056\/NEJMoa1114138","journal-title":"N Engl J Med"},{"issue":"19","key":"3446_CR9","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1056\/NEJMoa022340","volume":"348","author":"JA Child","year":"2003","unstructured":"Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ, Medical Research Council Adult Leukaemia Working P (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348(19):1875\u20131883. https:\/\/doi.org\/10.1056\/NEJMoa022340","journal-title":"N Engl J Med"},{"issue":"19","key":"3446_CR10","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","volume":"366","author":"PL McCarthy","year":"2012","unstructured":"McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Seiler M, Rosenbaum C, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Anderson KC, Linker C (2012) Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 366(19):1770\u20131781. https:\/\/doi.org\/10.1056\/NEJMoa1114083","journal-title":"N Engl J Med"},{"issue":"9","key":"3446_CR11","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1182\/blood.V99.9.3163","volume":"99","author":"JR Berenson","year":"2002","unstructured":"Berenson JR, Crowley JJ, Grogan TM, Zangmeister J, Briggs AD, Mills GM, Barlogie B, Salmon SE (2002) Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 99(9):3163\u20133168","journal-title":"Blood"},{"issue":"2","key":"3446_CR12","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1046\/j.1365-2141.1998.00795.x","volume":"102","author":"D Cunningham","year":"1998","unstructured":"Cunningham D, Powles R, Malpas J, Raje N, Milan S, Viner C, Montes A, Hickish T, Nicolson M, Johnson P, Treleaven J, Raymond J, Gore M (1998) A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. Br J Haematol 102(2):495\u2013502","journal-title":"Br J Haematol"},{"issue":"3","key":"3446_CR13","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1200\/JCO.1998.16.3.890","volume":"16","author":"SE Salmon","year":"1998","unstructured":"Salmon SE, Crowley JJ, Balcerzak SP, Roach RW, Taylor SA, Rivkin SE, Samlowski W (1998) Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study. J Clin Oncol 16(3):890\u2013896. https:\/\/doi.org\/10.1200\/JCO.1998.16.3.890","journal-title":"J Clin Oncol"},{"issue":"8","key":"3446_CR14","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1182\/blood-2012-02-408922","volume":"120","author":"L Rosinol","year":"2012","unstructured":"Rosinol L, Oriol A, Teruel AI, Hernandez D, Lopez-Jimenez J, de la Rubia J, Granell M, Besalduch J, Palomera L, Gonzalez Y, Etxebeste MA, Diaz-Mediavilla J, Hernandez MT, de Arriba F, Gutierrez NC, Martin-Ramos ML, Cibeira MT, Mateos MV, Martinez J, Alegre A, Lahuerta JJ, San Miguel J, Blade J, Programa para el Estudio y la Terapeutica de las Hemopatias Malignas\/Grupo Espanol de Mieloma g (2012) Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA\/GEM study. Blood 120(8):1589\u20131596. https:\/\/doi.org\/10.1182\/blood-2012-02-408922","journal-title":"Blood"},{"issue":"24","key":"3446_CR15","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","volume":"30","author":"P Sonneveld","year":"2012","unstructured":"Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H, Zweegman S, Vellenga E, Broyl A, Blau IW, Weisel KC, Wittebol S, Bos GM, Stevens-Kroef M, Scheid C, Pfreundschuh M, Hose D, Jauch A, van der Velde H, Raymakers R, Schaafsma MR, Kersten MJ, van Marwijk-Kooy M, Duehrsen U, Lindemann W, Wijermans PW, Lokhorst HM, Goldschmidt HM (2012) Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial. J Clin Oncol 30(24):2946\u20132955. https:\/\/doi.org\/10.1200\/JCO.2011.39.6820","journal-title":"J Clin Oncol"},{"issue":"19","key":"3446_CR16","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","volume":"366","author":"A Palumbo","year":"2012","unstructured":"Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, Gisslinger H, Wiktor-Jedrzejczak W, Zodelava M, Weisel K, Cascavilla N, Iosava G, Cavo M, Kloczko J, Blade J, Beksac M, Spicka I, Plesner T, Radke J, Langer C, Ben Yehuda D, Corso A, Herbein L, Yu Z, Mei J, Jacques C, Dimopoulos MA, Investigators MM (2012) Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 366(19):1759\u20131769. https:\/\/doi.org\/10.1056\/NEJMoa1112704","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"3446_CR17","doi-asserted-by":"publisher","first-page":"8001","DOI":"10.1200\/JCO.2016.34.15_suppl.8001","volume":"34","author":"Michel Attal","year":"2016","unstructured":"Attal M, Palumbo A, Holstein SA, Lauwers-Cances V, Petrucci MT, Richardson PG, Hulin C, Tosi P, Anderson KC, Caillot D, Magarotto V, Moreau P, Marit G, Yu Z, McCarth PL (2016) Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS). J Clin Oncol 34(suppl 15):8001\u20138001","journal-title":"Journal of Clinical Oncology"},{"issue":"9983","key":"3446_CR18","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","volume":"385","author":"C Rollig","year":"2015","unstructured":"Rollig C, Knop S, Bornhauser M (2015) Multiple myeloma. Lancet 385(9983):2197\u20132208. https:\/\/doi.org\/10.1016\/S0140-6736(14)60493-1","journal-title":"Lancet"},{"issue":"10","key":"3446_CR19","doi-asserted-by":"publisher","first-page":"e485","DOI":"10.1038\/bcj.2016.89","volume":"6","author":"B Lipe","year":"2016","unstructured":"Lipe B, Vukas R, Mikhael J (2016) The role of maintenance therapy in multiple myeloma. Blood Cancer J 6(10):e485. https:\/\/doi.org\/10.1038\/bcj.2016.89","journal-title":"Blood Cancer J"},{"issue":"12","key":"3446_CR20","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1007\/s00277-011-1224-1","volume":"90","author":"SG Verelst","year":"2011","unstructured":"Verelst SG, Termorshuizen F, Uyl-de Groot CA, Schaafsma MR, Ammerlaan AH, Wittebol S, Sinnige HA, Zweegman S, van Marwijk KM, van der Griend R, Lokhorst HM, Sonneveld P, Wijermans PW, Dutch-Belgium Hemato-Oncology Cooperative G (2011) Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial. Ann Hematol 90(12):1427\u20131439. https:\/\/doi.org\/10.1007\/s00277-011-1224-1","journal-title":"Ann Hematol"},{"issue":"9","key":"3446_CR21","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1182\/blood-2012-09-451872","volume":"121","author":"AK Stewart","year":"2013","unstructured":"Stewart AK, Trudel S, Bahlis NJ, White D, Sabry W, Belch A, Reiman T, Roy J, Shustik C, Kovacs MJ, Rubinger M, Cantin G, Song K, Tompkins KA, Marcellus DC, Lacy MQ, Sussman J, Reece D, Brundage M, Harnett EL, Shepherd L, Chapman JA, Meyer RM (2013) A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial. Blood 121(9):1517\u20131523. https:\/\/doi.org\/10.1182\/blood-2012-09-451872","journal-title":"Blood"},{"issue":"9","key":"3446_CR22","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.3109\/10428194.2015.1132419","volume":"57","author":"RM Rifkin","year":"2016","unstructured":"Rifkin RM, Abonour R, Shah JJ, Mehta J, Narang M, Terebelo H, Gasparetto C, Toomey K, Hardin JW, Lu JJ, Kenvin L, Srinivasan S, Knight R, Nagarwala Y, Durie BG (2016) Connect MM(R) - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide. Leuk Lymphoma 57(9):2228\u20132231. https:\/\/doi.org\/10.3109\/10428194.2015.1132419","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"3446_CR23","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.clml.2014.12.002","volume":"15","author":"RM Rifkin","year":"2015","unstructured":"Rifkin RM, Abonour R, Terebelo H, Shah JJ, Gasparetto C, Hardin J, Srinivasan S, Ricafort R, Nagarwala Y, Durie BG (2015) Connect MM registry: the importance of establishing baseline disease characteristics. Clin Lymphoma Myeloma Leuk 15(6):368\u2013376. https:\/\/doi.org\/10.1016\/j.clml.2014.12.002","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"3446_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/leu.2008.291","volume":"23","author":"RA Kyle","year":"2009","unstructured":"Kyle RA, Rajkumar SV (2009) Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 23(1):3\u20139. https:\/\/doi.org\/10.1038\/leu.2008.291","journal-title":"Leukemia"},{"issue":"2","key":"3446_CR25","first-page":"129","volume":"23","author":"CS Cleeland","year":"1994","unstructured":"Cleeland CS, Ryan KM (1994) Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singap 23(2):129\u2013138","journal-title":"Ann Acad Med Singap"},{"issue":"3","key":"3446_CR26","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/01.mlr.0000254515.63841.81","volume":"45","author":"AS Pickard","year":"2007","unstructured":"Pickard AS, De Leon MC, Kohlmann T, Cella D, Rosenbloom S (2007) Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients. Med Care 45(3):259\u2013263. https:\/\/doi.org\/10.1097\/01.mlr.0000254515.63841.81","journal-title":"Med Care"},{"issue":"5","key":"3446_CR27","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2165\/00019053-200725050-00002","volume":"25","author":"AS Pickard","year":"2007","unstructured":"Pickard AS, Wilke CT, Lin HW, Lloyd A (2007) Health utilities using the EQ-5D in studies of cancer. PharmacoEconomics 25(5):365\u2013384","journal-title":"PharmacoEconomics"},{"issue":"6","key":"3446_CR28","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.jpainsymman.2011.06.019","volume":"43","author":"LI Wagner","year":"2012","unstructured":"Wagner LI, Robinson D Jr, Weiss M, Katz M, Greipp P, Fonseca R, Cella D (2012) Content development for the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM): use of qualitative and quantitative methods for scale construction. J Pain Symptom Manag 43(6):1094\u20131104. https:\/\/doi.org\/10.1016\/j.jpainsymman.2011.06.019","journal-title":"J Pain Symptom Manag"},{"key":"3446_CR29","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1182\/blood.V128.22.1143.1143","volume":"128","author":"GH Jackson","year":"2016","unstructured":"Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C, Waterhouse A, Jones JR, Kishore B, Garg M, Williams CD, Karunanithi K, Lindsay J, Jenner MW, Cook G, Kaiser MF, Drayson MT, Owen RG, Russell NH, Gregory WM, Morgan GJ (2016) Lenalidomide is a highly effective maintenance therapy in myeloma patients of all ages; results of the phase III myeloma XI study. Blood 128:1143\u20131143","journal-title":"Blood"},{"issue":"5","key":"3446_CR30","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3324\/haematol.2012.074534","volume":"98","author":"MA Dimopoulos","year":"2013","unstructured":"Dimopoulos MA, Delforge M, Hajek R, Kropff M, Petrucci MT, Lewis P, Nixon A, Zhang J, Mei J, Palumbo A (2013) Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial. Haematologica 98(5):784\u2013788. https:\/\/doi.org\/10.3324\/haematol.2012.074534","journal-title":"Haematologica"},{"issue":"15","key":"3446_CR31","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J (2005) International staging system for multiple myeloma. J Clin Oncol 23(15):3412\u20133420. https:\/\/doi.org\/10.1200\/JCO.2005.04.242","journal-title":"J Clin Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-018-3446-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3446-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3446-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T08:17:21Z","timestamp":1571645841000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-018-3446-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,29]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["3446"],"URL":"https:\/\/doi.org\/10.1007\/s00277-018-3446-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,29]]},"assertion":[{"value":"30 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Rafat Abonour: Steering committee for Celgene, research funding from Celgene, Takeda, and Prothena; Lynne Wagner: consultancy for EveryFit, Gilead, and Janssen; Brian G. M. Durie: consultancy for Takeda and Janssen; Sundar Jagannath: consultancy for Bristol-Myers Squibb, Celgene, Merck, and Novartis,\u00a0speakers\u2019 bureau for MMRF and Medicom; Mohit Narang: consultancy and speakers\u2019 bureau for Celgene, speakers\u2019 bureau for Janssen;\u00a0Howard R. Terebelo: consultancy for Celgene, speakers\u2019 bureau for Janssen, Takeda, and Pharmacyclics; Cristina J. Gasparetto: consultancy for Celgene, Janssen, and Bristol-Myers Squibb research funding from Celgene, honoraria from Bristol-Myers Squibb, Celgene, Takeda, and Janssen, travel reimbursement from Janssen, Bristol-Myers Squibb, and Celgene; Kathleen Toomey: consultancy for Celgene, speakers\u2019 bureau for Myriad Genetics, travel reimbursement from Dava Oncology; James W. Hardin: consultancy for Celgene; Amani Kitali: employment\u00a0at Celgene; Craig Gibson: employment at Celgene (former); Shankar Srinivasan: employment at Celgene; Arlene S. Swern: employment at Celgene; Robert M. Rifkin: consultancy for Amgen, Boehringer Ingelheim, Celgene, EMD Serono, Sandoz, and Takeda, stock with McKesson.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}